This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pletnev, A. G.
Right arrow Articles by Elkins, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pletnev, A. G.
Right arrow Articles by Elkins, R.

 Previous Article  |  Next Article 

Journal of Virology, September 2001, p. 8259-8267, Vol. 75, No. 17
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.17.8259-8267.2001

Tick-Borne Langat/Mosquito-Borne Dengue Flavivirus Chimera, a Candidate Live Attenuated Vaccine for Protection against Disease Caused by Members of the Tick-Borne Encephalitis Virus Complex: Evaluation in Rhesus Monkeys and in Mosquitoes

Alexander G. Pletnev,1,* Michael Bray,2 Kathryn A. Hanley,1 Jim Speicher,1 and Randy Elkins1

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892,1 and Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 217022

Received 20 March 2001/Accepted 29 May 2001

Langat virus (LGT), strain TP21, a naturally avirulent tick-borne flavivirus, was used to construct a chimeric candidate virus vaccine which contained LGT genes for premembrane (preM) and envelope (E) glycoprotein and all other sequences derived from dengue type 4 virus (DEN4). The live virus vaccine was developed to provide resistance to the highly virulent, closely related tick-borne flaviviruses that share protective E epitopes among themselves and with LGT. Toward that end the chimera, initially recovered in mosquito cells, was adapted to grow to high titer in qualified simian Vero cells. When inoculated intraperitoneally (i.p.), the Vero cell-adapted LGT TP21/DEN4 chimera remained completely attenuated for SCID mice. Significantly, the chimera protected immunocompetent mice against the most virulent tick-borne encephalitis virus (TBEV). Subsequently, rhesus monkeys were immunized in groups of 4 with 105 or 107 PFU of LGT strain TP21, with 105 PFU of DEN4, or with 103, 105, or 107 PFU of the chimera. Each of the monkeys inoculated with DEN4 or LGT TP21 became viremic, and the duration of viremia ranged from 1 to 5 days. In contrast, viremia was detected in only 1 of 12 monkeys inoculated with the LGT TP21/DEN4 chimera; in this instance the level of viremia was at the limit of detection. All monkeys immunized with the chimera or LGT TP21 virus developed a moderate to high level of neutralizing antibodies against LGT TP21 as well as TBEV and were completely protected against subsequent LGT TP21 challenge, whereas monkeys previously immunized with DEN4 virus became viremic when challenged with LGT TP21. These observations suggest that the chimera is attenuated, immunogenic, and able to induce a protective immune response. Furthermore, passive transfer of serum from monkeys immunized with chimera conferred significant protection to mice subsequently challenged with 100 i.p. 50% lethal doses of the highly virulent TBEV. The issue of transmissibility of the chimera by mosquitoes was addressed by inoculating a nonhematophagous mosquito, Toxorhynchites splendens, intrathoracically with the chimera or its DEN4 or LGT parent. Neither the LGT TP21/DEN4 vaccine candidate nor the wild-type LGT TP21 virus was able to infect this mosquito species, which is highly permissive for dengue viruses. Certain properties of the chimera, notably its attenuation for monkeys, its immunogenicity, and its failure to infect a highly permissive mosquito host, make it a promising vaccine candidate for use in immunization against severe disease caused by many tick-borne flaviviruses.


* Corresponding author. Mailing address: Building 7, Room 236, NIAID, NIH, 7 Center Dr., MSC 0740, Bethesda, MD 20892. Phone: (301) 402-7754. Fax: (301) 496-8312. E-mail: apletnev{at}niaid.nih.gov.


Journal of Virology, September 2001, p. 8259-8267, Vol. 75, No. 17
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.17.8259-8267.2001



This article has been cited by other articles:

  • Maximova, O. A., Ward, J. M., Asher, D. M., St. Claire, M., Finneyfrock, B. W., Speicher, J. M., Murphy, B. R., Pletnev, A. G. (2008). Comparative Neuropathogenesis and Neurovirulence of Attenuated Flaviviruses in Nonhuman Primates. J. Virol. 82: 5255-5268 [Abstract] [Full Text]  
  • Chambers, T. J., Jiang, X., Droll, D. A., Liang, Y., Wold, W. S. M., Nickells, J. (2006). Chimeric Japanese encephalitis virus/dengue 2 virus infectious clone: biological properties, immunogenicity and protection against dengue encephalitis in mice.. J. Gen. Virol. 87: 3131-3140 [Abstract] [Full Text]  
  • Romero, T. A., Tumban, E., Jun, J., Lott, W. B., Hanley, K. A. (2006). Secondary structure of dengue virus type 4 3' untranslated region: impact of deletion and substitution mutations.. J. Gen. Virol. 87: 3291-3296 [Abstract] [Full Text]  
  • Calvert, A. E., Huang, C. Y.-H., Kinney, R. M., Roehrig, J. T. (2006). Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. J. Gen. Virol. 87: 339-346 [Abstract] [Full Text]  
  • Best, S. M., Morris, K. L., Shannon, J. G., Robertson, S. J., Mitzel, D. N., Park, G. S., Boer, E., Wolfinbarger, J. B., Bloom, M. E. (2005). Inhibition of Interferon-Stimulated JAK-STAT Signaling by a Tick-Borne Flavivirus and Identification of NS5 as an Interferon Antagonist. J. Virol. 79: 12828-12839 [Abstract] [Full Text]  
  • Pletnev, A. G., Putnak, R., Speicher, J., Wagar, E. J., Vaughn, D. W. (2002). From the Cover: West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc. Natl. Acad. Sci. USA 99: 3036-3041 [Abstract] [Full Text]